Jefferies Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $21.8M | Sell |
67,267
-22,387
| -25% | -$7.09M | 0.18% | 87 |
|
|
2022
Q2 | $29.1M | Sell |
89,654
-7,747
| -8% | -$2.33M | 0.24% | 63 |
|
|
2022
Q1 | $27.9M | Buy |
97,401
+73,045
| +300% | +$18.8M | 0.18% | 88 |
|
|
2021
Q4 | $6.73M | Buy |
24,356
+12,806
| +111% | +$3.25M | 0.04% | 378 |
|
|
2021
Q3 | $2.67M | Buy |
11,550
+9,732
| +535% | +$2.4M | 0.02% | 654 |
|
|
2021
Q2 | $417K | Sell |
1,818
-10,127
| -85% | -$2.03M | ﹤0.01% | 1221 |
|
|
2021
Q1 | $2.23M | Sell |
11,945
-8,866
| -43% | -$1.73M | 0.02% | 638 |
|
|
2020
Q4 | $3.51M | Sell |
20,811
-42,174
| -67% | -$6.3M | 0.03% | 529 |
|
|
2020
Q3 | $9.32M | Buy |
62,985
+52,043
| +476% | +$8.05M | 0.1% | 160 |
|
|
2020
Q2 | $1.8K | Sell |
10,942
-20,064
| -65% | -$3.08M | 0.02% | 588 |
|
|
2020
Q1 | $4.3M | Buy |
31,006
+19,363
| +166% | +$2.66M | 0.05% | 369 |
|
|
2019
Q4 | $1.53M | Sell |
11,643
-13,601
| -54% | -$1.58M | 0.01% | 1201 |
|
|
2019
Q3 | $2.82M | Sell |
25,244
-50,544
| -67% | -$5.63M | 0.02% | 854 |
|
|
2019
Q2 | $8.4M | Buy |
75,788
+66,490
| +715% | +$7.83M | 0.06% | 274 |
|
|
2019
Q1 | $1.21M | Sell |
9,298
-78,834
| -89% | -$9.59M | 0.01% | 1180 |
|
|
2018
Q4 | $10.2M | Sell |
88,132
-11,528
| -12% | -$1.29M | 0.08% | 194 |
|
|
2018
Q3 | $10.7M | Buy |
99,660
+80,692
| +425% | +$8.07M | 0.07% | 249 |
|
|
2018
Q2 | $1.62M | Buy |
18,968
+11,265
| +146% | +$925K | 0.01% | 998 |
|
|
2018
Q1 | $596K | Sell |
7,703
-254,155
| -97% | -$20.5M | ﹤0.01% | 1412 |
|
|
2017
Q4 | $22.1M | Buy |
261,858
+205,712
| +366% | +$17.5M | 0.1% | 114 |
|
|
2017
Q3 | $4.8M | Sell |
56,146
-69,749
| -55% | -$5.72M | 0.03% | 548 |
|
|
2017
Q2 | $10.4M | Buy |
125,895
+120,317
| +2,157% | +$9.82M | 0.07% | 265 |
|
|
2017
Q1 | $469K | Sell |
5,578
-50,953
| -90% | -$4.08M | ﹤0.01% | 1618 |
|
|
2016
Q4 | $4.16M | Buy |
56,531
+22,657
| +67% | +$1.69M | 0.02% | 641 |
|
|
2016
Q3 | $2.72M | Sell |
33,874
-50,630
| -60% | -$4.05M | 0.01% | 792 |
|
|
2016
Q2 | $6.66M | Buy |
84,504
+28,883
| +52% | +$2.17M | 0.03% | 398 |
|
|
2016
Q1 | $4M | Sell |
55,621
-51,235
| -48% | -$3.88M | 0.02% | 567 |
|
|
2015
Q4 | $9M | Sell |
106,856
-18,951
| -15% | -$1.57M | 0.05% | 292 |
|
|
2015
Q3 | $10.5M | Buy |
125,807
+38,195
| +44% | +$3.22M | 0.06% | 251 |
|
|
2015
Q2 | $7.31M | Buy |
87,612
+35,435
| +68% | +$2.7M | 0.04% | 386 |
|
|
2015
Q1 | $3.79M | Sell |
52,177
-35,335
| -40% | -$2.52M | 0.02% | 517 |
|
|
2014
Q4 | $6.04M | Buy |
87,512
+54,271
| +163% | +$3.66M | 0.04% | 370 |
|
|
2014
Q3 | $2.16M | Sell |
33,241
-287
| -0.9% | -$18.2K | 0.01% | 698 |
|
|
2014
Q2 | $2.08M | Buy |
33,528
+28,242
| +534% | +$1.69M | 0.02% | 618 |
|
|
2014
Q1 | $311K | Sell |
5,286
-13,084
| -71% | -$730K | ﹤0.01% | 1512 |
|
|
2013
Q4 | $937K | Buy |
18,370
+1,156
| +7% | +$57.9K | 0.01% | 862 |
|
|
2013
Q3 | $866K | Sell |
17,214
-35,556
| -67% | -$1.86M | 0.01% | 966 |
|
|
2013
Q2 | $2.59M | Buy |
+52,770
| New | +$2.87M | 0.03% | 404 |
|
Other funds holding LLY
Jefferies Group's LLY Position: Q3 2022 in Review
Jefferies Group reduced its Eli Lilly (LLY) stake by 25% in Q3 2022, selling an estimated $7.09M and leaving 67,267 shares worth $21.8M. The position accounts for 0.18% of the portfolio, ranked #87.
Jefferies Group first reported a position in LLY in Q2 2013 and has held it in 38 quarters since. The position peaked at $29.1M in Q2 2022. 2,484 funds tracked by Wall St. Rank hold LLY as of Q3 2022.
- Jefferies Group held 67,267 shares of Eli Lilly worth $21.8M as of Q3 2022.
- Jefferies Group sold 22,387 Eli Lilly shares in Q3 2022, an estimated $7.09M.
- Eli Lilly made up 0.18% of Jefferies Group's portfolio in Q3 2022, its #87 holding.
- Jefferies Group first reported a position in Eli Lilly in Q2 2013 and has held it in 38 quarters since.
- Jefferies Group's Eli Lilly position peaked at $29.1M in Q2 2022.
- 2,484 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.
Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.